Azurity Pharmaceuticals, Inc. portfolio
United States
Every trademark Azurity Pharmaceuticals, Inc. holds, newest filings first. The portfolio has 125 marks filed under 13 owner names.
Search this portfolio
- Trademarks on file
- 125
- Active
- 96
- Owner names grouped
- 13
Portfolio
All trademarks
50 marks per page, newest filing date first. Pick an office to narrow the list.
| Mark | Status | Office | Classes | Filed |
|---|---|---|---|---|
| FINREYIS | examining | USPTO | 5 | 2026-10-21 |
| ZESBLI | examining | USPTO | 5 | 2026-10-13 |
| ESLINZI | examining | USPTO | 5 | 2026-10-13 |
| NILDANZY | mixed | WIPO | 5 | 2026-09-10 |
| NILDANZY | pending opposition | EUIPO | 5 | 2026-09-09 |
| FITLEXBY | pending opposition | USPTO | 5 | 2026-07-16 |
| FLEXTEMVO | pending opposition | USPTO | 5 | 2026-07-16 |
| BUILT FOR REAL LIFE | pending opposition | USPTO | 40, 44 | 2026-06-23 |
| LAMQUIRA | allowed | USPTO | 5 | 2025-11-20 |
| LAMLIQUE | allowed | USPTO | 5 | 2025-11-20 |
| RESNIBEN | mixed | WIPO | 5 | 2025-10-30 |
| ABANTA | allowed | USPTO | 5 | 2025-08-27 |
| JAVADIN | registered | WIPO | 5 | 2025-07-18 |
| AZURITY | mixed | WIPO | 5 | 2025-06-16 |
| AZURITY | pending issuance | USPTO | 5 | 2025-06-06 |
| RESNIBEN | allowed | USPTO | 5 | 2025-04-30 |
| FIRVANQ | registered | WIPO | 5 | 2025-04-09 |
| ENLYTOR | abandoned | USPTO | 5 | 2025-04-08 |
| ARYNTA | registered | USPTO | 5 | 2025-04-08 |
| NAVGI 360 | registered | USPTO | 42, 44 | 2025-03-03 |
| NAVGI 360 | registered | USPTO | 42, 44 | 2025-03-03 |
| JAVADIN | registered | USPTO | 5 | 2025-01-21 |
| REZMENTA | abandoned | USPTO | 5 | 2024-12-19 |
| DANZITEN | mixed | WIPO | 5 | 2024-11-15 |
| LOCABO | abandoned | USPTO | 5 | 2024-10-23 |
| DANZITEN CONNECT | registered | USPTO | 35, 36, 44, 45 | 2024-10-15 |
| [Design Mark] | registered | USPTO | 5 | 2024-09-25 |
| [Design Mark] | registered | USPTO | 5 | 2024-08-13 |
| ATUNIST | abandoned | USPTO | 5 | 2024-08-13 |
| VIVIMUSTA CONNECT | registered | USPTO | 35, 36, 44 | 2024-08-01 |
| RINTIVA | abandoned | USPTO | 5 | 2024-04-09 |
| SERVING OVERLOOKED PATIENTS | mixed | WIPO | 40, 44 | 2024-04-05 |
| AZURITY SOLUTIONS E-Z RX | registered | USPTO | 35, 44 | 2024-03-07 |
| RINHIBLY | abandoned | USPTO | 5 | 2024-01-23 |
| DANZITEN | registered | USPTO | 5 | 2024-01-12 |
| NIBERA | abandoned | USPTO | 5 | 2024-01-12 |
| AZMIRO | registered | USPTO | 5 | 2023-11-17 |
| XIFYRM | registered | USPTO | 5 | 2023-10-31 |
| MYCOSORA | abandoned | USPTO | 5 | 2023-10-31 |
| MYHIBBIN | registered | USPTO | 5 | 2023-10-31 |
| SISTENZIV | abandoned | USPTO | 5 | 2023-10-31 |
| SERVING OVERLOOKED PATIENTS | registered | USPTO | 40, 44 | 2023-10-06 |
| HAVLIDUR | abandoned | USPTO | 5 | 2023-05-23 |
| BRYNOVIN | registered | USPTO | 5 | 2023-05-23 |
| PREVDUO | registered | USPTO | 5 | 2022-11-30 |
| ADTHYZA (THYROID TABLETS, USP) | registered | USPTO | 5 | 2022-08-08 |
| SERVING OVERLOOKED PATIENTS | registered | USPTO | 5 | 2022-04-29 |
| AZURITY SOLUTIONS E-Z RX | abandoned | USPTO | 35 | 2022-03-25 |
| VIVIMUSTA | registered | USPTO | 5 | 2022-03-23 |
| FLEQSUVY | registered | WIPO | 5 | 2021-12-02 |
API
Get this data via the API
Everything on this page comes from the Signa API. Pull Azurity Pharmaceuticals, Inc.'s full portfolio into your own product.
GET/v1/entities/{id}/trademarksEvery trademark in the portfolio, filterable by office and class
GET/v1/entities/{id}/analyticsPortfolio totals, disputes and ownership changes
GET/v1/entities/{id}Company record, ticker, LEI and owner names
GET /v1/entities/{id}/trademarks
ID=ent_019eb725-e6a7-73db-81c8-7bbc8473b1bf
curl https://api.signa.so/v1/entities/$ID/trademarks \
-H "Authorization: Bearer $SIGNA_API_KEY"Response
{
"object": "list",
"data": [
{
"id": "tm_01a163b6-e662-76f9-8f37-fd9a802fb8aa",
"mark_text": "FINREYIS",
"office_code": "US",
"status": {
"stage": "examining"
},
"filing_date": "2026-10-21"
},
{
"id": "tm_01a13a86-0471-729f-96ec-552663eb33d0",
"mark_text": "ZESBLI",
"office_code": "US",
"status": {
"stage": "examining"
},
"filing_date": "2026-10-13"
}
],
"has_more": true
}